{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117760","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.288611+00:00","generated_at":"2026-06-21T20:13:55.185267+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jaguar Health Q3 prescription revenue $3.1M (+412% YoY); net loss widens to $12.5M","bullets":["Prescription product net revenue $3.1M in Q3 2022, up 8.2% QoQ and 412% YoY vs $0.6M.","Net loss $12.5M ($0.12/sh) vs $12.2M loss in Q3 2021; operating loss $9.9M vs $9.5M.","R&D expense rose to $5.9M from $3.3M driven by Phase 3 crofelemer CTD trial.","OnTarget Phase 3 CTD trial targets enrollment completion in Q2 2023.","Non-GAAP EBITDA loss $8.5M, flat YoY; no guidance provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117760","json":"https://secwatch.observer/filing/0001104659-22-117760.json","markdown":"https://secwatch.observer/filing/0001104659-22-117760.md","text":"https://secwatch.observer/filing/0001104659-22-117760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465922117760/0001104659-22-117760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465922117760/tm2230421d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:13:55.185267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea722f0899ac6994cefba286d5a6dd7aa90fe36b","claim":"Jaguar Health, Inc. reported third quarter 2022 results: revenue approximately $3.1 million.","evidence_excerpt":"The combined net revenue for Mytesi ® and the Company’s other prescription product, Canalevia ® -CA1, which became commercially available in April 2022, was approximately $3.1 million in the third quarter of 2022, representing an increase of 8.2% over prescription product net revenue in the second quarter of 2022, which totaled approximately $2.9 million, and an increase of approximately 412% over Mytesi net revenue in the third quarter of 2021, which totaled approximately $0.6 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465922117760/0001104659-22-117760-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2022"},{"label":"Revenue","value":"approximately $3.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}